FDA hits Supernus with double whammy, handing biotech a CRL and RTF on same day
Supernus had a bad Monday.
Yesterday, the Maryland biotech announced that two different therapies had been shot back by the …
Sign up to read this article for free.
Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.
